Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy

Area of Science:

• Maternal-Fetal Medicine
• Biomarker Discovery
• Clinical Diagnostics

Background:

• Hypertensive disorders of pregnancy pose risks for severe preeclampsia (sPE).
• Accurate risk stratification is crucial for timely intervention.
• Biomarkers may improve prediction of sPE development.

Purpose of the Study:

• To evaluate the prognostic performance of the serum sFlt-1:PlGF ratio in predicting sPE.
• To assess the ratio's ability to stratify risk for adverse maternal outcomes.
• To compare the ratio's predictive accuracy against standard clinical measures.

Main Methods:

• Prospective measurement of serum sFlt-1:PlGF ratio in 1014 pregnant women hospitalized between 23-35 weeks gestation across 18 U.S. centers.
• Derivation and validation cohort design to assess prognostic performance for sPE prediction.
• Analysis of secondary outcomes including adverse maternal events within 2 weeks.

Main Results:

• A sFlt-1:PlGF ratio of ≥40 demonstrated significant predictive value for sPE (65% positive, 96% negative predictive value in validation cohort).
• The ratio showed superior performance (AUC 0.92) compared to standard clinical measures (<0.75).
• Women with a ratio ≥40 faced a 5.8-fold higher risk of adverse maternal outcomes.

Conclusions:

• Serum sFlt-1:PlGF ratio measurement effectively stratifies risk for developing sPE in women with hypertensive disorders of pregnancy.
• This biomarker aids in identifying pregnancies at high risk for imminent severe complications.
• The findings support the clinical utility of the sFlt-1:PlGF ratio for improved maternal-fetal care.